NEW YORK (GenomeWeb News) – Celera reported after the close of the market on Tuesday that its fourth-quarter revenues rose 15 percent year over year, while the firm swung from a profit to a loss on increased SG&A spending.

The Alameda, Calif.-based personalized disease management products firm brought in revenues of $47.3 million for the three-month period ended Dec. 27, compared to revenue of $40.3 million for the three-month period ended Dec. 31, 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.